科前生物(688526) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥292,893,681.48, representing a year-on-year increase of 26.97%[8] - The net profit attributable to shareholders for Q3 2022 was ¥124,316,091.34, an increase of 24.61% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥116,998,185.12, reflecting a 19.49% increase year-on-year[8] - Total operating revenue for the first three quarters of 2022 was CNY 686,519,778.45, a decrease from CNY 775,730,840.29 in the same period of 2021[41] - Net profit for the third quarter of 2022 was CNY 283,242,940.68, down from CNY 385,906,499.83 in the same quarter of 2021[44] - Basic earnings per share for the third quarter of 2022 were CNY 0.61, compared to CNY 0.83 in the same quarter of 2021[47] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥4,112,287,808.95, a 10.39% increase from the end of the previous year[11] - The equity attributable to shareholders at the end of Q3 2022 was ¥3,362,357,143.43, which is a 6.62% increase compared to the previous year[11] - Total liabilities as of the reporting date were CNY 747,676,688.12, an increase from CNY 571,411,688.95 in the previous year[38] - Non-current liabilities totaled CNY 109,565,365.15, compared to CNY 79,167,052.81 in the previous year, reflecting growth[38] - The total current liabilities increased to CNY 70,057,000.00 from CNY 18,028,402.78, showing a significant rise of about 288.5%[36] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥331,129,993.39, a decrease of 30.11% compared to the previous year[11] - The net cash flow from operating activities was 331,129,993.39, a decrease of 30% compared to 473,820,698.63 from the previous period[51] - Cash inflow from investment activities totaled 1,087,055,180.09, up from 909,195,036.22, indicating a growth of approximately 19.6%[51] - The net cash flow from investment activities was -342,129,625.01, slightly worse than -314,670,837.11 from the previous period[51] - Cash inflow from financing activities was 79,984,913.26, down from 94,377,295.80, reflecting a decline of about 15.3%[52] - The net cash flow from financing activities was -84,584,534.30, an improvement compared to -115,994,664.61 in the previous period[52] Research and Development - The R&D investment totaled ¥20,721,031.10 for Q3 2022, an increase of 11.80% compared to the same period last year[11] - The R&D investment as a percentage of operating revenue was 7.07%, a decrease of 0.96 percentage points year-on-year[11] - The company has established a cooperation framework agreement with Huazhong Agricultural University for future R&D projects[24] - The company invested a total of RMB 9,630,743.93 in the research of the genetically engineered live vaccine for pseudorabies, with ongoing laboratory research[25] - The company has a cumulative investment of RMB 12,283,223.40 in the research of the genetically engineered live vaccine for infectious bovine rhinotracheitis, currently in laboratory research[25] - The company is actively involved in laboratory research for various vaccines, including the rabies virus inactivated vaccine, which is part of its ongoing product development strategy[27] Product Development - The company has obtained 39 new veterinary drug registration certificates, with 29 obtained through collaboration with Huazhong Agricultural University[24] - The company has registered 10 new veterinary drugs through third-party collaborations[24] - The company has invested RMB 8,100,512.69 in the research of the inactivated vaccine for porcine circovirus type 2 and Actinobacillus pleuropneumonia, with new veterinary drug registration achieved[25] - The company has invested RMB 468,859.81 in the research of the live vaccine for Mycoplasma bovis, with new veterinary drug registration achieved[25] - The company has invested RMB 616,943.07 in the research of the inactivated vaccine for porcine delta coronavirus, with new veterinary drug registration achieved[25] - The company is pursuing clinical trials for new vaccines, including the dual inactivated vaccine for swine fever and pseudorabies, indicating a focus on innovation and market expansion[36] Shareholder Information - The company has a total of 10,915,000 shares held by the controlling shareholder, Mu Yuan Industrial Group Co., Ltd.[23]